Market Research Logo

Conference Documentation: RNA Therapeutics

Conference Documentation: RNA Therapeutics

The 2016 RNA Therapeutics conference will hone in on some key developments currently shaping the industry, and putting the spotlight on messenger RNA-based Therapeutics.

We will review clinical trial updates in oncology, cardiovascular injury, and ophthalmology, and open the floor for discussion to review existing and emerging concepts in delivery systems, oligonucleotides, aptamer-conjugates as well as messenger RNA therapeutics.

The biggest challenge in enabling RNAi therapy is transporting RNA to target sites outside the liver, and so having targeted delivery systems, which can optimise bioavailability and controllable kinetics remains an issue. However, with exciting concepts such as polymeric nanoparticles and viral vectors as a new class of carriers existing on the horizon, the conference will look at the future of these technologies.

Moreover, messenger RNA (mRNA) is attracting considerable interest for its ability to restore gene expression and correct protein production. Thus, we will anticipate what new avenues will open up in gene- based therapies.


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
9:10
Pre-clinical and clinical experience with oligonucleotide drugs
Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
9:50
A new class of RNA therapeutics – RIG-I
Christian Schetter, Chief Executive Office and Managing Director, Rigontec GmbH
10:30
Morning Coffee
11:00
Sponsored session: Single Copy Detection of Specific Transcripts in the Tissue
Kai Wilkens, Senior Director Europe, Advanced Cell Diagnostics SRL
11:40
RNA vaccines development and optimising mRNA therapeutics and delivery
Mustafa Diken, Deputy Vice President Immunotherapies and Preclinical Research , BioNTech AG
12:20
Networking Lunch
13:30
Keynote address: Systematic delivery of anti-sense oligonucleotides through ligand-conjugate chemistry
Punit Seth, Executive Director, Isis Pharmaceuticals
14:10
Silencing of gene expression with oligonucleotides and modifiable pharmacologic profile
Juergen Soutschek, Consultant , Biotechnology
14:50
Keynote Address: Rational design including functionalization of nanoparticles for improved cell delivery
Christianne Rijcken, CSO, Cristal Therapeutics
15:30
Afternoon Tea
16:00
Biotech 2.0 – Medical revolution through natural mRNA
Nigel Horscroft, Director, Alliance Management, CureVac
16:40
Regulating nano therapeutics and commercial interests
Brian Kelly, Associate, Covington & Burling LLP
17:20
Panel discussion: Pushing towards and clinical success and market authorisation
Nagy Habib, Professor of Surgery, Chairman and Co-Founder, Imperial College London, MiNA Therapeutics
17:20
Panel discussion: Pushing towards and clinical success and market authorisation
Nigel Horscroft, Director, Alliance Management, CureVac
17:20
Panel discussion: Pushing towards and clinical success and market authorisation
Christian Schetter, Chief Executive Office and Managing Director, Rigontec GmbH
17:20
Panel discussion: Pushing towards and clinical success and market authorisation
Juergen Soutschek, Consultant , Biotechnology
17:20
Panel discussion: Pushing towards and clinical success and market authorisation
Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
18:00
Chairman’s Closing Remarks and Close of Day One
Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Nagy Habib, Professor of Surgery, Chairman and Co-Founder, Imperial College London, MiNA Therapeutics
9:10
OPENING ADDRESS: RNA Activation with small activating RNA: liver application
Nagy Habib, Professor of Surgery, Chairman and Co-Founder, Imperial College London, MiNA Therapeutics
9:50
Keynote address: Keynote address: How does the functionalisation of nanoparticles improve cell delivery
Claude Paul Malvy, Co-head of research group: Chemical Vectorology of anticancer drugs, , Gustave Roussy Institute
10:30
Morning Coffee
11:00
Small interfering RNA in targeting eye conditions
Covadonga Paneda, R&D Manager, Sylentis
11:40
The therapeutic utility of mRNA for the expression of therapeutic proteins
Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech AG
12:20
Networking Lunch
13:30
Functional RNA delivery through precision therapeutics beyond the liver
Andrew Miller, CSO, GlobalAcorn Ltd
14:10
Time to consider Freedom to Operate?
James Legg, European and UK Patent Attorney , Boult Wade Tennant
14:50
Novel properties sought from chemically-modified oligonucleotide molecules
C.I. Edvard Smith, Professor, Karolinska Institutet
15:30
Afternoon Tea
16:00
Aptamers as delivery vehicles targeting tumour cells
David Bunka, CEO, Aptamer group
16:40
Panel discussion: Decentralizing research and more collaboration
Nagy Habib, Professor of Surgery, Chairman and Co-Founder, Imperial College London, MiNA Therapeutics
17:20
Chairman’s Closing Remarks and Close of Day Two
Nagy Habib, Professor of Surgery, Chairman and Co-Founder, Imperial College London, MiNA Therapeutics

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report